Sophie Uyoga
Biographic Data
| ID | 7023281 |
|---|---|
| NAME | Sophie Uyoga |
| GIVEN NAMES | Sophie |
| FAMILY NAME | Uyoga |
| SIGNATURE | UYOGA S |
| AFFILIATIONS | Kenya Medical Research Institute |
| ORCID | 0000-0003-1746-7873 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Epidemiological impact and cost-effectiveness analysis of Covid-19 vaccination in Kenya
BACKGROUND: A few studies have assessed the epidemiological impact and the cost-effectiveness of COVID-19 vaccines in settings where most of the population had been exposed to SARS-CoV-2 infection. METHODS: We conducted a cost-effectiveness analysis of COVID-19 vaccine in Kenya from a societal perspective over a 1.5-year time frame. An age-structured transmission model assumed at least 80% of the population to have prior natural immunity when an …
Sars-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
Background Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. We conducted population-based serosurveys at three Health and Demographic Surveillance Systems (HDSSs) to determine the cumulative incidence of infection with SARS-CoV-2. Methods We selected random age-stratified population-based samples at HDSSs in Kisumu, Nai…
Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi
ISRCTN ISRCTN84086586
No prominent works on this page.
Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi
ISRCTN ISRCTN84086586
Epidemiological impact and cost-effectiveness analysis of Covid-19 vaccination in Kenya
BACKGROUND: A few studies have assessed the epidemiological impact and the cost-effectiveness of COVID-19 vaccines in settings where most of the population had been exposed to SARS-CoV-2 infection. METHODS: We conducted a cost-effectiveness analysis of COVID-19 vaccine in Kenya from a societal perspective over a 1.5-year time frame. An age-structured transmission model assumed at least 80% of the population to have prior natural immunity when an …
Sars-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
Background Most of the studies that have informed the public health response to the COVID-19 pandemic in Kenya have relied on samples that are not representative of the general population. We conducted population-based serosurveys at three Health and Demographic Surveillance Systems (HDSSs) to determine the cumulative incidence of infection with SARS-CoV-2. Methods We selected random age-stratified population-based samples at HDSSs in Kisumu, Nai…
Immunology (3 works) · Medicine (3 works) · Environmental health (2 works) · Epidemiology (2 works) · Internal Medicine (2 works) · SARS-CoV-2 and COVID-19 Research (2 works) · 2019-20 coronavirus outbreak (1 works) · Anemia (1 works) · Biology (1 works) · Biostatistics (1 works)